Drug intelligence / Profile preview

DNB-101

Development stage: Preclinical
Lead developer: De Novo Biotherapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DNB-101 is an mRNA-based bispecific natural killer (NK) cell engager being developed by De Novo Biotherapeutics for the treatment of non-Hodgkin's lymphoma. The therapeutic candidate utilizes mRNA technology to express a bispecific antibody designed to simultaneously target CD20 on malignant B cells and activate NK cells, promoting the immunological destruction of CD20-positive tumor cells. Currently, DNB-101 is in the lead optimization stage of preclinical development.

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on DNB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNB-101.

Explore the full profile